利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

51 条记录 (耗时 0.028 秒)

    CDCA1-DERIVED PEPTIDE AND VACCINE CONTAINING SAME
    2.
    发明公开
    CDCA1-DERIVED PEPTIDE AND VACCINE CONTAINING SAME 审中-公开

    公开(公告)号：EP4282883A2

    公开(公告)日：2023-11-29

    申请号：EP23194566.8

    申请日：2015-07-31

    申请人： OncoTherapy Science, Inc.

    发明人： TSUNODA, Takuya ,  OSAWA, Ryuji ,  YAMASHITA, Sachiko ,  WATANABE, Tomohisa

    IPC分类号： C07K16/28

    摘要： The present invention provides CDCA1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.

    KNTC2 PEPTIDES AND VACCINES CONTAINING THE SAME
    4.
    发明公开
    KNTC2 PEPTIDES AND VACCINES CONTAINING THE SAME 审中-公开
    KNTC2-PEPTIDE UND IMPFSTOFFE DAMIT

    公开(公告)号：EP2970944A1

    公开(公告)日：2016-01-20

    申请号：EP14763683.1

    申请日：2014-03-11

    申请人： OncoTherapy Science, Inc.

    发明人： TSUNODA, Takuya ,  OSAWA, Ryuji ,  YOSHIMURA, Sachiko ,  WATANABE, Tomohisa

    IPC分类号： C12N15/00 ,  A61K38/00 ,  A61K39/00 ,  C07K14/435 ,  C07K16/30 ,  C12N5/0783 ,  C12N5/0784

    CPC分类号： A61K39/0011 ,  A61K38/00 ,  A61K2039/5154 ,  C07K7/06 ,  C07K14/47 ,  C07K16/18 ,  G01N33/505 ,  G01N33/57484

    摘要： Peptide vaccines against cancer are described herein. In particular, isolated epitope peptides derived from the KNTC2 gene that elicit CTLs and thus are suitable for use in the context of cancer immunotherapy are provided. The inventive peptides encompass both KNTC2 -derived peptides and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite CTL inducibility of the original sequences. Further provided are polynucleotides encoding such peptides as well as pharmaceutical compositions that include any such peptides or polynucleotides as active agents. Antigen-presenting cells and isolated CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. Furthermore, the present invention provides methods for the treatment and/or prophylaxis (i.e., prevention) of cancers (tumors), and/or the prevention of a metastatic- or post-operative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the peptides derived from KNTC2, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.

    摘要翻译： 本文描述了针对癌症的肽疫苗。 特别地，提供了衍生自引起CTL的KNTC2基因并因此适用于癌症免疫治疗的上下文中的分离的表位肽。 本发明的肽包括来源于KNTC2的肽及其修饰形式，只要这些修饰形式保留了原始序列的必需的CTL诱导性。

    UBE2T PEPTIDES AND VACCINES CONTAINING THE SAME
    5.
    发明公开
    UBE2T PEPTIDES AND VACCINES CONTAINING THE SAME 审中-公开
    UBE2T-4-PEPTIDE UND IMPFSTOFFE DAMIT

    公开(公告)号：EP2895600A1

    公开(公告)日：2015-07-22

    申请号：EP13837757.7

    申请日：2013-09-09

    申请人： OncoTherapy Science, Inc.

    发明人： TSUNODA, Takuya ,  OSAWA, Ryuji ,  YOSHIMURA, Sachiko ,  WATANABE, Tomohisa

    IPC分类号： C12N9/00 ,  A61K31/7088 ,  A61K39/00 ,  A61P35/00 ,  C07K16/18 ,  C07K16/40 ,  C12N5/10 ,  C12N15/09 ,  G01N33/15

    CPC分类号： A61K39/0011 ,  A61K31/7088 ,  A61K2039/5154 ,  C07K16/40 ,  C12N9/93 ,  C12Y603/02019 ,  G01N33/57492

    摘要： Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the UBE2T that elicit CTLs are provided. Isolated antigen-presenting cells with CTL inducibility and CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing such epitope peptides derived from UBE2T or polynucleotides encoding the polypeptides as active ingredients. Furthermore, the present invention provides methods for the treatment and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or the prevention of a postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the epitope peptides derived from UBE2T, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.

    摘要翻译： 本文描述了针对癌症的肽疫苗。 特别地，提供了衍生自引发CTL的UBE2T的表位肽。 还提供了具有CTL诱导能力的分离的抗原呈递细胞和靶向这些肽的CTL，以及诱导抗原呈递细胞或CTL的方法。 本发明还提供了含有衍生自UBE2T的表位肽或编码多肽作为活性成分的多核苷酸的药物组合物。 此外，本发明提供了治疗和/或预防（即预防）癌症（肿瘤）和/或预防其术后复发的方法，以及诱导CTL的方法，诱导抗肿瘤的方法 免疫，使用衍生自UBE2T的表位肽，编码肽的多核苷酸或呈递肽的抗原呈递细胞，或本发明的药物组合物。

    IQGAP3 EPITOPE PEPTIDES AND VACCINES CONTAINING THE SAME
    7.
    发明公开
    IQGAP3 EPITOPE PEPTIDES AND VACCINES CONTAINING THE SAME 审中-公开
    IQGAP3表位肽和疫苗含

    公开(公告)号：EP2303909A1

    公开(公告)日：2011-04-06

    申请号：EP09762266.6

    申请日：2009-06-10

    申请人： Oncotherapy Science, Inc.

    发明人： TSUNODA, Takuya ,  OHSAWA, Ryuji ,  YOSHIMURA, Sachiko ,  WATANABE, Tomohisa

    IPC分类号： C07K4/12 ,  A61K39/00 ,  A61P35/00 ,  C07K7/06 ,  C07K14/74 ,  C12N5/06 ,  C12N15/09

    CPC分类号： C07K14/4722 ,  A61K39/0011 ,  C07K7/06 ,  C07K14/4706

    摘要： Peptide vaccines against cancer are described herein. In particular, the present invention describes epitope peptides derived from IQGAP3 that elicit CTLs. The present invention also provides established CTLs that specifically recognize HLA-A24 or HLA-A02 positive target cells pulsed with the peptides. Antigen-presenting cells and exosomes that present any of the peptides, as well as methods for inducing antigen-presenting cells are also provided. The present invention further provides pharmaceutical agents containing the IQGAP3 polypeptides or polynucleotides encoding thereof, as well as exosomes and antigen-presenting cells as active ingredients. Furthermore, the present invention provides methods for treating and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or prevention of postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the IQGAP3 polypeptides, polynucleotides encoding the polypeptides, exosomes or antigen-presenting cells presenting the polypeptides, or the pharmaceutical agents of the present invention. The cancers to be targeted include, but are not limited to, renal, esophageal, gastric, lung, breast, bladder and pancreatic cancer.